NEW IBS research highlights persistent pain treatment gaps and points to peripheral nerve targets for future, safer therapies.<\/p>\n
IBS Pain Remains a Major Clinical Gap<\/p>\n
Pain remains one of the most difficult symptoms to treat in irritable bowel syndrome (IBS)<\/a>, according to a new review examining unmet needs in current care and the promise of future therapies aimed at peripheral visceral afferent pathways. While existing IBS management often focuses on bowel dysfunction or central neuromodulators, the review argues that safe and effective pain control is still the field\u2019s greatest unmet need.<\/p>\n The paper outlines how visceral signals travel from the gut to the brain through vagal and pelvic parasympathetic pathways, while noxious stimuli are transmitted through visceral afferents and the spinal cord. This physiology has sharpened interest in the dorsal root ganglion, where first order sensory neuron cell bodies express multiple receptors that may be therapeutically relevant in IBS pain.<\/p>\n IBS Pain Treatment and Peripheral Visceral Afferent Modulation<\/p>\n The review centers on peripheral visceral afferent modulation as a possible new direction for IBS pain treatment<\/a>. Advances in the understanding of visceral hypersensitivity have led to growing interest in receptors expressed on dorsal root ganglia, particularly as potential drug targets that may reduce pain without relying on centrally acting approaches.<\/p>\n Among the receptor systems discussed are \u03b12 adrenergic, somatostatin SS2, 5-HT3, cannabinoid, nicotinic cholinergic, calcitonin gene related peptide, \u03ba opioid, GLP-1 receptors, and acid gated ion channels. These targets have shown promise in rodent models of visceral hypersensitivity, and some have supporting evidence from randomized controlled trials in IBS.<\/p>\n A Potential Alternative to Central Neuromodulators<\/p>\n